Bangladesh Everest Pharmaceuticals
Bangladesh Everest Pharmaceuticals is a well-known pharmaceutical company in Bangladesh, primarily focused on the production of generic medicines. The company operates its own R&D center and multiple manufacturing facilities. In recent years, Everest Pharmaceuticals has made notable progress in international markets and has partnered with China’s Yaodirect to provide high-quality generic drugs to Chinese patients, helping to reduce their medication costs.
As one of the leading enterprises in the pharmaceutical industry, Everest has achieved remarkable success in areas such as research and development, manufacturing, and marketing. The company boasts a highly skilled R&D team, including several PhD-level experts, and invests millions of dollars annually in new product development and technological upgrades. It holds over 300 domestic and international patents, and its products are available in more than 30 countries and regions worldwide.
One of Everest's core strengths lies in its strong influence in the generic drug market. Generic drugs are not only more affordable but also offer equivalent quality and efficacy compared to branded drugs, leading to growing international demand. By leveraging its advanced technology and management expertise, Everest has significantly expanded its generic drug R&D and production, successfully entering both domestic and international markets.
Everest Pharmaceuticals – Key Milestones
🔹 2014–2015: Company Founding and Facility Construction
-
Everest Pharmaceuticals was established, with a goal of becoming one of the first Bangladeshi companies to meet EU cGMP standards.
-
Invested in building state-of-the-art manufacturing facilities using imported equipment from Germany and Italy.
-
Construction began on sterile production lines designed to meet EU GMP and UK MHRA standards.
🔹 2016–2018: Production License and Domestic Market Launch
-
Received approval from the Bangladesh Directorate General of Drug Administration (DGDA) and officially began production.
-
Entered the domestic market with products covering antibiotics, cardiovascular, diabetes, and oncology drugs.
-
Established a dedicated Quality Control Laboratory (QC Lab) aligned with ICH guidelines.
🔹 2019–2020: Targeting Export Markets
-
Completed preparations for multiple international registrations and began exporting generic medicines to Southeast Asia, the Middle East, and Africa.
-
Initiated regulatory alignment for entering Europe and the U.S., and applied for EU GMP inspections.
-
Established partnerships with international distributors using a dual strategy of CDMO (Contract Development and Manufacturing Organization) and private label collaborations.
🔹 2021: EU GMP Certification Achieved
-
Successfully passed EU GMP certification, recognized by the European Medicines Agency (EMA)—becoming one of the few Bangladeshi companies qualified to export to the EU.
-
Began producing EU-standard tablets, capsules, and injectables, including oncology, antiviral, cardiovascular, and diabetic medications.
🔹 2022–2023: Expansion into Oncology and Advanced Formulations
-
Launched injectable oncology drugs and oral targeted therapies such as generic Erlotinib and Afatinib.
-
Collaborated with several European CROs for bioequivalence (BE) studies and technology transfers.
-
Established a lyophilized (freeze-dried) injectable line, preparing to enter the high-end sterile product market.
🔹 2024–Present: Deepening Global Strategy
-
Opened regional offices in the Middle East, Africa, and Latin America.
-
Began development of biosimilars and complex formulations such as liposomal drugs, orally disintegrating tablets (ODTs), and nanoparticle-based therapies.
-
Initiated the U.S. FDA approval process, with the goal of entering the North American market.
